Table 4:

Desensitization outcomes

Characteristic	N = 186
Median time in chemo unit, minutes (range)	380 (325, 630)
Median number of desensitization cycles, n (range)	3 (1, 28)
Successful completion of 3 or more cycles, n (%)	104 (56%)
Breakthrough HSR during desensitization, n (%)	79 (42%)
Reason for drug discontinuation, n (%)
Progression of disease	84 (45%)
Hypersensitivity reaction*	41 (22%)
End of treatment	38 (20%)
Other	13 (7%)
Ongoing	10 (5%)
*Drugs discontinued due to breakthrough HSR (N = 41)
Oxaliplatin	20 (49%)
Carboplatin	14 (34%)
Cisplatin	2 (5%)
Paclitaxel	2 (5%)
Trastuzumab	2 (5%)
Liposomal doxorubicin	1 (2%)

HSR, hypersensitivity reaction